
Timothy J Pluard MD
Breast Cancer
Koontz Endowed Chair in Breast Disease, University of Missouri, Kansas City School of Medicine. Director Saint Luke's Cancer Institute
Join to View Full Profile
4401 Wornall RdKansas City, MO 64111
Phone+1 816-932-3800
Fax+1 816-932-3888
Dr. Pluard is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1991 - 1993
- University of Texas Southwestern Medical CenterResidency, Internal Medicine, 1987 - 1991
- Washington University in St. Louis School of MedicineClass of 1987
Certifications & Licensure
- MO State Medical License 1993 - 2026
- KS State Medical License 2014 - 2024
- FL State Medical License 2020 - 2022
- TX State Medical License 1988 - 1992
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer Start of enrollment: 2011 Sep 01
- A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation Start of enrollment: 2012 Aug 01
- Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer Start of enrollment: 2012 Dec 11
- Join now to see all
Publications & Presentations
PubMed
- Effects of Lasofoxifene Versus Fulvestrant on Vaginal and Vulvar Symptoms in Patients With ESR1-Mutated, ER+/HER2-, Metastatic Breast Cancer From the ELAINE 1 Study.Shari B Goldfarb, Sarah L Sammons, Jane L Meisel, Timothy J Pluard, Simon N Jenkins
Clinical Breast Cancer. 2025-04-01 - Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocri...Lowell L Hart, Seock-Ah Im, Sara M Tolaney, Mario Campone, Timothy Pluard
European Journal of Cancer. 2025-02-25 - 1 citationsReal-world quality-of-life of patients with HR+/HER2- advanced breast cancer treated with palbociclib plus endocrine therapy: EORTC QLQ-C30 results from POLARIS.Gabrielle B Rocque, Joanne L Blum, Yan Ji, Timothy Pluard, John Migas
Breast Cancer Research and Treatment. 2025-02-01
Press Mentions
- The Power of Metastatic Breast Cancer Retreats with Lillie Shockney and Janie Metsker: Part 1October 28th, 2022
- Saint Luke's Cancer Institute & Patient Discovery Launches Innovative Digital Advocate for Advance Care PlanningJune 10th, 2021
- Anova Announces Formation of Scientific Advisory Board to Advance Development of Its Technology Platform Transforming Clinical DevelopmentOctober 7th, 2020
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: